Associations of PNPLA3 rs738409 Polymorphism with Plasma Lipid Levels: A Systematic Review and Meta-Analysis

Abstract

Accumulating evidence has shown that the rs738409 polymorphism of patatin-like phospholipase domain-containing 3 (PNPLA3) is associated with non-alcoholic fatty liver disease (NAFLD). Since NAFLD has been reported to be associated with lipid metabolism, this study is conducted to explore whether the rs738409 polymorphism of PNPLA3 was associated with lipid levels. By searching PubMed and the Cochrane database from May 31, 2020, to June 30, 2021. Sixty-three studies (81 003 subjects) were included for the analysis. The consistent findings for the associations of rs738409 polymorphism with lipid levels were the significantly decreased triglycerides (TG) (SMD=−0.04, 95% CI=−0.07 to −0.01, p=0.02) and total cholesterol (TC) (SMD=−0.03, 95% CI=−0.05 to −0.01, p<0.01) levels. Subgroup analysis indicated that the associations of rs738409 polymorphism with TG and TC levels were stronger in Caucasians, obesity patients, and adult subjects than in Asians, T2DM patients, and children subjects. The rs738409 polymorphism of PNPLA3 was associated with lower TG and TC levels in Caucasians, obese and adult subjects, which may contribute to the reduced coronary artery disease (CAD) risk between PNPLA3 rs738409 polymorphism and CAD.

Key words

PNPLA3 - rs738409 - polymorphism - lipids and cholesterol - CAD

Publication History

Received: 22 January 2022

Accepted after revision: 11 August 2022

Article published online:
07 October 2022

• References

• 1 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219
• 2 Speliotes EK, Yerges-Armstrong LM, Wu J. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Gene 2011; 7: e1001324
• 3 Namjou B, Lingren T, Huang Y. et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Med 2019; 17: 135
• 4 Kozlitina J, Smagris E, Stender S. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46: 352-356
• 5 Trépo E, Romeo S, Zucman-Rossi J. et al. PNPLA3 gene in liver diseases. J Hepatol 2016; 6: 399-412
• 6 Pingitore P, Romeo S. The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids 2019; 1864: 900-906
• 7 Baclig MO, Lozano-Kühne JP, Mapua CA. et al. Genetic variation I148M in patatin-like phospholipase 3 gene and risk of non-alcoholic fatty liver disease among Filipinos. Int J Clin Exp Med 2014; 7: 2129-2136
• 8 Jenkins CM, Mancuso DJ, Yan W. et al. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 2004; 279: 48968-48975
• 9 Pingitore P, Romeo S. The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids 2019; 1864: 900-906
• 10 Chamoun Z, Vacca F, Parton RG. et al. PNPLA3/adiponutrin functions in lipid droplet formation. Biol Cell 2013; 105: 219-233
• 11 Qiao A, Liang J, Ke Y. et al. Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. Hepatology 2011; 54: 509-521
• 12 He S, McPhaul C, Li JZ. et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-6715
• 13 Pirazzi C, Adiels M, Burza MA. et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 2012; 57: 1276-1282
• 14 Kumari M, Schoiswohl G, Chitraju C. et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012; 15: 691-702
• 15 Rüschenbaum S, Schwarzkopf K, Friedrich-Rust M. et al. Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events. Hepatol Commun 2018; 2: 798-806
• 16 Tang CS, Zhang H, Cheung CY. et al. Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. Nat Commun 2015; 6: 10206
• 17 Yusuf S, Hawken S, Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952
• 18 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: 1-34
• 19 Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 Updated September 2006. The Cochrane Collaboration 2006; 1-256
• 20 DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28: 105-114
• 21 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101
• 22 BasuRay S, Wang Y, Smagris E. et al. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A 2019; 116: 9521-9526
• 23 BasuRay S, Smagris E, Cohen JC. et al. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology 2017; 66: 1111-1124
• 24 Smagris E, BasuRay S, Li J. et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015; 61: 108-118
• 25 Hu J, Zhang Z, Shen WJ. et al. Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab (Lond) 2010; 7: 47
• 26 Shimobayashi SF, Ohsaki Y. Universal phase behaviors of intracellular lipid droplets. Proc Natl Acad Sci U S A 2019; 116: 25440-25445
• 27 Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 2011; 286: 37085-37093
• 28 Mittelstraß K, Waldenberger M. DNA methylation in human lipid metabolism and related diseases. Curr Opin Lipidol 2018; 29: 116-124
• 29 Kitamoto T, Kitamoto A, Ogawa Y. et al. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. J Hepatol 2015; 63: 494-502
• 30 Carr RM, Ahima RS. Pathophysiology of lipid droplet proteins in liver diseases. Exp Cell Res 2016; 340: 187-192
• 31 Tsai WT, Nakamura Y, Akasaka T. et al. Soyasaponin ameliorates obesity and reduces hepatic triacylglycerol accumulation by suppressing lipogenesis in high-fat diet-fed mice. J Food Sci 2021; 86: 2103-2117
• 32 WHO European Regional Obesity Report 2022. Copenhagen: WHO Regional Office for Europe; 2022. Available online https://www.who.int/europe/publications/i/item/9789289057738
• 33 Janssen F, Bardoutsos A, Vidra N. Obesity prevalence in the long-term future in 18 European countries and in the USA. Obes Facts 2020; 13: 514-527